GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors
-
Published:2024-08
Issue:
Volume:
Page:
-
ISSN:2213-1779
-
Container-title:JACC: Heart Failure
-
language:en
-
Short-container-title:JACC: Heart Failure
Author:
Patel Rushin,
Wadid Mark,
Makwana Bhargav,
Kumar Ashish,
Khadke Sumanth,
Bhatti Ammar,
Banker Ahan,
Husami Zaid,
Labib Sherif,
Venesy David,
Fonarow GreggORCID,
Kosiborod Mikhail,
Al-Kindi Sadeer,
Bhatt Deepak L.ORCID,
Dani Sourbha,
Nohria AnjuORCID,
Butler Javed,
Ganatra Sarju
Reference31 articles.
1. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes;Marso;N Engl J Med,2016
2. Liraglutide and cardiovascular outcomes in type 2 diabetes;Marso;N Engl J Med,2016
3. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action;Ussher;Nat Rev Cardiol,2023
4. Role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity;Michos;J Am Heart Assoc,2023
5. Semaglutide and cardiovascular outcomes in obesity without diabetes;Lincoff;N Engl J Med,2023